Clinical trials: Patient Derived Organoid
Pancreas Neoplasms, Pancreatic Neoplasms
Predictive Value of Transcriptome-based OncoTreat/Oncotarget and Organoid Testing in Metastatic Pancreatic Cancer.
Pancreatic cancer is burdened by a survival of barely 10% at 5 years. About 80% of new cases do not qualify for surgery due to either locally-advanced or metastatic disease.
- Conditions
- Pancreas Neoplasms, Pancreatic Neoplasms, Pancreatic Cancer Metastatic, Pancreatic Adenocarcinoma Metastatic
- Trial name
- NCT06615830
- Volunteers
- 185 people
- Sponsor
- Prof. Dr. med. Dres. h.c. Jan Schmidt, MME
HER2-negative Breast Cancer, Advanced Breast Cancer
Organoid-based Functional Precision Therapy for Advanced Breast Cancer
This is a phase II, multicenter, open-label, randomized controlled trial to compare the efficacy of organoid-guided treatment (OGT) to treatment of physician's choice (TPC) in previously treated, HER2-negative locally advanced or…
- Trial name
- ORIENTA (NCT06102824)
- Testing
- Organoid-guided treatment, Taxane, Capecitabine
- Where
- China
- Volunteers
- 252 people
- Sponsor
- Guangdong Provincial People's Hospital
Primary Tumor, Colon Tumor
Tumor Immune Microenvironment Involvement in Colorectal Cancer Chemoresistance Mechanisms
Colorectal cancer is the third most common cancer worldwide and its progression-free survival is still low, around 10 months. Thirthy to 50% of patients do not respond to chemotherapy upon initiation of treatment, suggesting that…
- Trial name
- CRC-ORGA2 (NCT05038358)
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Grenoble
Spondyloarthritis, Inflammatory Bowel Diseases
Validation of a Preclinical Model Based on Patient-derived Organoids for the Study of the Gut-joint Axis in Spondyloarthritis
This project aims to develop and validate a model of human organoids derived from patients with Spondyloarthritis, focusing on synovial and intestinal tissues as targets of the gut-joint axis.
- Trial name
- ORGANOSPA (NCT06421116)
- Testing
- Synovial ultrasound-guided biopsy Intestinal biopsy
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Colon Cancer, Organoids
Cetuximab Sensitivity Correlation Between Patient-Derived Organoids and Clinical Response in Colon Cancer Patients.
Eighty patients with RAS/RAF wild-type metastatic right colon cancer will be enrolled and undergo a fresh biopsy of tumor lesion before the standard treatment of chemotherapy.
- Conditions
- Colon Cancer, Organoids, Metastatic Cancer
- Trial name
- NCT04906733
- Testing
- Tumor biopsy
- Where
- China
- Volunteers
- 80 people
- Sponsor
- D1 Medical Technology (Shanghai) Co., Ltd, China
Prostate Cancer, Prostate Cancer Metastatic Disease
Lab Research Using Mini-tumors to Study Prostate Cancer Treatments
For men with an aggressive form of prostate cancer, finding the right and effective treatment right away is challenging. Many of these men face a high risk of cancer recurrence: about half experience a relapse after surgery, and…
- Conditions
- Prostate Cancer, Prostate Cancer Metastatic Disease, Prostate Cancer Recurrent, Advanced Prostate Cancer
- Trial name
- PR3DICT (NCT07004582)
- Testing
- HDR brachytherapy, Diagnostic biopsy
- Where
- 3 sites in Netherlands
- Volunteers
- 600 people
- Sponsor
- Maastricht Radiation Oncology
Glioma, Astrocytic
Evaluation of ex Vivo Drug Combination Optimization Platform in Recurrent High Grade Astrocytic Glioma
This is an interventional, non-randomized, single site study. Brain tumor samples will be collected from patients for organoids generation and subject to panel drugs screening and QPOP analysis to derive the optimal drug…
- Trial name
- NCT05532397
- Testing
- QPOP category 1, QPOP category 2
- Where
- 2 sites in Singapore
- Volunteers
- 10 people
- Sponsor
- National University Hospital, Singapore
Rare Tumour
Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS
The objective of this Phase II, open-label, multicenter, non-randomised controlled clinical trial is to guide precision treatment for patients with rare tumours based on Patient-Derived Organoids/Next-Generation Sequencing drug…
- Trial name
- SPRING (NCT06692491)
- Testing
- Albumin-Bound Paclitaxel, Epirubicin, Gemcitabine
- Volunteers
- 200 people
- Sponsor
- Peking University Shenzhen Hospital
Pancreas Cancer
Evaluation and Comparison of the Growth Rate of Pancreatic Cancer Patient-derived Organoids
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive forms of cancer. Despite advances in the understanding of the mechanisms underlying PDAC pathogenesis, the impact on patient benefit is lagging.
- Trial name
- NCT03990675
- Testing
- FNA, FNB
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Technical University of Munich
Lung Neoplasm
Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer
Create a living biobank of PDOs from Stage I-III lung cancer patients.
- Trial name
- NCT03655015
- Testing
- Lung Tumor Resection
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Lung Cancer
Lung Cancer Organoids and Patient Derived Tumor Xenografts
Extra tissue will be taken from patient during a procedure in standard of care. Also, through an existing line, 10ml of extra blood will be drawn.
- Trial name
- IPON-3 (NCT05092009)
- Testing
- Tissue and blood
- Where
- 3 sites in Netherlands
- Volunteers
- 600 people
- Sponsor
- Maastricht Radiation Oncology
Glioma
Organoids Derived From Induced-Pluripotent Stem Cells (iPS) From Patients With High Grade Astrocytoma
The objective of this study research proposal is to model human gliomagenesis using 3-Dimensional (3D) brain organoids derived from human induced pluripotent stem cells (hiPSCs).
- Trial name
- GLIOMANOID (NCT03971812)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Bladder Cancer, Non-muscle Invasive Bladder Cancer
Precise Chemoresection in Low-grade NMIBC Using Drug Screens in Patient-derived Organoids
Based on the unmet clinical need to reduce invasiveness of treatment of low grade NMIBC, the investigators conduct this prospective, open label, single arm and single center phase II trial.
- Conditions
- Bladder Cancer, Non-muscle Invasive Bladder Cancer, Low Grade
- Trial name
- POLO (NCT06227065)
- Testing
- Epirubicin, Mitomycin, Gemcitabine
- Where
- 2 sites in Switzerland
- Volunteers
- 28 people
- Sponsor
- Hospital Centre Biel/Bienne
Breast Cancer, Locally Advanced Breast Cancer (LABC)
Patient-Derived Organoids to Functionally Characterize Chemotherapy Resistance in Breast Cancer
This prospective observational study aims to functionally characterize chemotherapy resistance in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy.
- Trial name
- BC-PDO (NCT07516626)
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Atlas University
Liver Cancer, Metastatic Liver Cancer
PDO/PDO-TIL/PDOTS for Drug Screen
This clinical trial aims to use the patient-derived organoid (PDO), Patient-derived organoids-tumor-infiltrating lymphocyte coculture system (PDO-TIL) and patient-derived organotypic tissue spheroids (PDOTS) to simulate the tumor…
- Trial name
- NCT05913141
- Testing
- Drug screen with PDO/PDO-TIL/PDOTS
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Zhongshan Hospital
Colorectal Neoplasms
Tailoring Treatment in Colorectal Cancer
In this study, the investigators will establish a reliable method and logistic pipeline for personalized drug testing ex vivo using fresh tumor samples from colorectal cancer (CRC) patients.
- Trial name
- TargetCRC (NCT05401318)
- Testing
- Tumor tissue sampling for organoid development
- Where
- Norway
- Volunteers
- 40 people
- Sponsor
- University Hospital, Akershus
Low-grade Glioma, High Grade Glioma
A Living Tissue Bank of Patient-Derived Organoids From Glioma Tumors
There is a high medical need to improve treatment outcome for high-grade and low-grade glioma since no curative treatment is available.
- Trial name
- HiLoGlio (NCT04865315)
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- Maastricht Radiation Oncology
Advanced Biliary Tract Cancer(BTC)
A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Biliary Tract Cancers
This is a prospective, non-randomized, open-label, single-center phase II clinical trial. It aims to evaluate the efficacy and feasibility of using patient-derived tumor organoid drug sensitivity testing (ODST) to guide…
- Trial name
- NCT07351591
- Testing
- Organoid Drug Sensitivity Testing-Guided Therapy
- Volunteers
- 88 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Bladder Cancer, Non-muscle Invasive
Guiding Instillation in Non Muscle-invasive Bladder Cancer Based on Drug Screens in Patient Derived Organoids
From patients with intermediate risk non-muscle invasive bladder cancer tumor (NMIBC) specimens will be harvested during transurethral resection. Fresh specimens will be cultured as patient derived organoids (PDO). After approx.
- Trial name
- GAIN-INST (NCT05024734)
- Testing
- Epirubicin, Mitomycin, Gemcitabine
- Where
- Switzerland
- Volunteers
- 31 people
- Sponsor
- Roland Seiler-Blarer
Breast Cancer
Study to Determine the Antitumor Activity of New CAR-macrophages in Breast Cancer Patients' Derived Organoids
Cell-based immune therapy using modified macrophages is a promising therapeutic approach in breast cancer. The objective of this cohort study is to collect tumor samples to develop patients' derived organoids to test the…
- Trial name
- CARMA (NCT05007379)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Centre Oscar Lambret